Evaluation of serum osteoprotegerin and fetuin A levels in Egyptian patients with chronic kidney disease

Comparative Clinical Pathology

Volumn 20, Issue 5, 2011, Pages 421-425

  Nessim, Iris Girgis ^a   el Wahab, Amal Abd ^d   Madani, Hanan Ali ^d   Waked, Emam ^b   el Khalek, Ashraf Abd ^c   Mabrouk, Khaled ^a  

^a Theodor Bilharz Research Institute   (Egypt)

^b El Nile St Warak Elhadar   (Egypt)

^c THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^d CAIRO UNIVERSITY   (Egypt)

Author keywords

CKD; Fetuin A; Osteoprotegerin; Vascular calcification

Indexed keywords

EID: 80052277768     PISSN: 16185641     EISSN: 1618565X     Source Type: Journal    
DOI: 10.1007/s00580-011-1281-9     Document Type: Review

References (31)

1. Bargnoux AS, Dupuy AM, Garrigue V, Deleuze S, Cristol JP, Mourad G (2006) Renal transplantation decreases osteoprotegerin levels. Transplant Proc 38: 2317-2318.
2. Block GA, Spiegel DM, Ehrlich J et al (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1824.
3. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337-342.
4. Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B (2008) Serum fetuin-A concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract 108: c233-c240. doi: 10. 1159/000120209.
5. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, Manni M, Morosetti M, Moscaritolo E, Sardella D, Bonucci E (2002) Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 17: 233-238.
6. Cottone S, Palermo A, Arsena R, Riccobene R, Guarneri M, Mulè G et al (2010) Relationship of fetuin-A with glomerular filtration rate and endothelial dysfunction in moderate-severe chronic kidney disease. JNEPHROL 23(01): 62-69.
7. Cozzolino M, Biondi ML, Galassi A et al (2007) Gene polymorphisms and serum alpha-2-Heremans-Schmid levels in Italian haemodialysis patients. Am J Nephrol 27: 639-642.
8. El-Abbadi M, Giachelli CM (2007) Mechanisms of vascular calcification. Adv Chronic Kidney Dis 14: 54-66.
9. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 32(Suppl 5): S112-S119.
10. Grzegorzewska AE, Mlot M (2004) Serum osteoprotegerin level is lower in peritoneal dialysis patients than hemodialysis ones. Rocz Akad Med Bialymst 49: 193-196.
11. Jono S, Shioi A, Ikari Y, Nishizawa Y (2006) Vascular calcification in chronic kidney disease. J Bone Miner Metab 24: 176-181.
12. Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y et al (2002) Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39: 525-532.
13. Ketteler M, Bongartz P, Westenfeld R (2003) Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361: 827-833.
14. Ketteler M, Gross ML, Ritz E (2005) Calcification and cardiovascular problems in renal failure. Kidney Int 94(Suppl): S120-S127.
15. Khamis T (2005) Epidemiology of chronic renal failure in Egypt. J Med Sci 5(7): 825-829.
16. Leung L (1993) Histidine-rich glycoprotein: an abundant plasma protein in search of a function. J Lab Clin Med 121: 630-631.
17. Moe SM, Chen NX (2004) Pathophysiology of vascular calcification in chronic kidney disease. Cir Res 95: 560-567.
18. Moe SM, Chen NX (2005) Inflammation and vascular calcification. Blood Purif 23: 64-71.
19. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L et al (2006) Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 17: 262-270.
20. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2suppl 1): S1-S266.
21. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ (2005) Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 10: 1793-1800.
22. Price PA, Lim JE (2003) The inhibition of calcium phosphate precipitation by fetuin is accompanied by the formation of a fetuin-mineral complex. J Biol Chem 278: 22144-22152.
23. Price PA, June HH, Buckley JR (2001) Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21: 1610-1616.
24. Sarnak MJ, Levey AS (2000) Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35(4 suppl 1): S117-S131.
25. Sato T, Tominaga Y, Iwasaki Y, Kazama JJ, Shigematsu T, Inagaki H et al (2001) Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis 38(Suppl 1): S175-S177.
26. Schafer C, Heiss A, Schwarz A (2003) The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112: 357-366.
27. Shroff RC, Shah V, Hiorns MP et al (2008) The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 23: 3263-3271.
28. Tonelli M, Pfeffer MA (2007) Kidney disease and cardiovascular risk. Annu Rev Med 58: 123-139.
29. Vattikuti R, Towler DA (2004) Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab 286: E686-E696.
30. Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, Liu SF, Li PK, Sanderson JE (2005) Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 20: 1676-1685.
31. Westenfeld R, Jahnen-Dechent W, Ketteler M (2007) Vascular calcification and fetuin-A deficiency in chronic kidney disease. Trends Cardiovasc Med 17: 124-128.